Life Seal Vascular recently announced that it has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant. The funding will be used to accelerate the development of the company’s endovascular aneurysm repair (EVAR) technology.
“We are honored to receive this prestigious SBIR grant from the NSF. This funding is a testament to the innovative potential of our technology and our commitment to advancing EVAR care,” said Bob Mitchell, executive chairman of the board at Life Seal Vascular.
He continued: “With this support, we are well positioned to advance the development of our breakthrough aneurysm sealing solutions and make a significant impact on the lives of EVAR patients worldwide.”
Life Seal Vascular notes that the NSF SBIR grant will enable the company to further develop its proprietary aneurysmal sac sealing technology. Designed as an adjunctive therapy to native endografts, Life Seal Vascular’s approach seals the entire aneurysmal sac potentially eliminating endoleaks, reducing reintervention rates and improving clinical outcomes for EVAR patients.
Vascular surgeon Michel Reijnen (Rijnstate Hospital, Arnhem, The Netherlands) commented on the significance of Life Seal Vascular’s technology, stating: “The advancements being made by Life Seal Vascular are truly remarkable. Their innovative solutions have the potential to revolutionise EVAR, offering patients safer and more effective treatment options. I am excited to see the positive impact this technology will have on the field and on patient care.”
A press release details that the NSF SBIR program is a highly competitive initiative that supports scientific excellence and technological innovation through the investment of federal research funds.
